Stratec (ETR:SBS) received a €66.00 ($76.74) price objective from equities research analysts at Warburg Research in a research report issued to clients and investors on Monday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. Warburg Research’s price objective indicates a potential downside of 5.85% from the company’s previous close.
Separately, Berenberg Bank set a €71.00 ($82.56) price objective on Stratec and gave the company a “buy” rating in a research note on Thursday, August 22nd.
ETR SBS opened at €70.10 ($81.51) on Monday. The business’s 50-day moving average price is €71.17 and its two-hundred day moving average price is €63.24. Stratec has a 12 month low of €49.00 ($56.98) and a 12 month high of €77.60 ($90.23). The firm has a market capitalization of $841.75 million and a PE ratio of 82.96. The company has a current ratio of 2.75, a quick ratio of 1.53 and a debt-to-equity ratio of 55.71.
Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers.
Further Reading: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Stratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec and related companies with MarketBeat.com's FREE daily email newsletter.